SGK Expands Coverage to Include Hemophilia and Cancer Drugs, Boosting Reimbursement Scope

SGK’s inclusion of two hemophilia B drugs and a cancer medication into its reimbursement list reshapes Turkey’s healthcare spending and social security budget.

DETAILED POLICY UPDATES

■2 hemophilia B drugs and 1 cancer drug added, alongside 3 locally produced medications.

■Reimbursement for magistral drugs increased by 40%.

■Pediatric surgery coverage expanded, yielding a 15% cost reduction.

■Bone marrow transplant processes updated, shortening treatment duration by 30 days.

ECONOMIC IMPACTS: BUDGET AND COMMERCIAL LOANS

■The policy is projected to add 1.5 billion TL to SGK’s annual outlay.

■This could exert a 0.3% inflationary pressure by 2025.

■Financial institutions anticipate a 5% rise in demand for health‑related loans.

■Short‑term bond issuance may increase by 1.2% to finance the added costs.

INDUSTRY AND INVESTOR OUTLOOK

■Local pharmaceutical firms report a 20% increase in market share.

■Foreign investors see a 8% growth potential in Turkey’s health‑insurance sector.

■Health‑sector ETFs rose 3.4% in the market.

FUTURE PATHWAY: HEALTH INSURANCE INNOVATION

■Expanded coverage strengthens public‑private collaboration.

■Investment in digital health platforms and tele‑medicine is recommended for long‑term cost control.

■Insurers are redesigning risk‑pricing models in response to the new coverage.

Kerem Tufan: SGK’s expansion eases cost pressures in the health sector while potentially boosting demand for health‑related commercial credit, especially among SMEs. However, the short‑term fiscal strain may prompt a modest rise in risk premiums within the banking sector.